Christine Mikail Cvijic

CIK: 0001543663

Transaction Breakdown

Open Market Buys (P)1 (6.3%)

High conviction signal

Open Market Sales (S)13 (81.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (12.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NGNE

Neurogene Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (16 total)

NGNE
Neurogene Inc.
Jul 7, 2026
Sale(S)
Direct
4.2K shares at avg. $36.13$152K
NGNE
Neurogene Inc.
Jul 6, 2026
Sale(S)
Direct
600 shares at avg. $36.02$22K
NGNE
Neurogene Inc.
Jul 2, 2026
Sale(S)
Direct
1.5K shares at avg. $35.23$54K
NGNE
Neurogene Inc.
Jul 2, 2026
Sale(S)
Direct
2.5K shares at avg. $34.58$88K
NGNE
Neurogene Inc.
Jul 1, 2026
Sale(S)
Direct
739 shares at avg. $34.06$25K
NGNE
Neurogene Inc.
May 6, 2026
Sale(S)
Direct
4.8K shares at avg. $30.07$144K
NGNE
Neurogene Inc.
May 6, 2026
Sale(S)
Direct
4.8K shares at avg. $32.44$156K
NGNE
Neurogene Inc.
Mar 26, 2026
Sale(S)
Direct
2.6K shares at avg. $21.62$55K
NGNE
Neurogene Inc.
Mar 13, 2026
Sale(S)
Direct
263 shares at avg. $22.02$6K
NGNE
Neurogene Inc.
Mar 13, 2026
Sale(S)
Direct
2.4K shares at avg. $20.42$49K
NGNE
Neurogene Inc.
Mar 13, 2026
Sale(S)
Direct
1.4K shares at avg. $21.25$30K
NGNE
Neurogene Inc.
Feb 27, 2026
Sale(S)
Direct
4.8K shares at avg. $25.11$121K
NGNE
Neurogene Inc.
Feb 20, 2026
Award(A)
Direct
22K shares-
NGNE
Neurogene Inc.
Mar 26, 2025
Award(A)
Direct
20.3K shares-
NGNE
Neurogene Inc.
Mar 13, 2025
Sale(S)
Direct
4.5K shares at avg. $16.94$76K
NGNE
Neurogene Inc.
Nov 22, 2024
Purchase(P)
Direct
24K shares at avg. $20.48$491K

		Type	Shares	Price		Ownership
Jul 7, 2026	NGNE Neurogene Inc.	Sale(S)	4,200	$36.13	$151,763	Direct
Jul 6, 2026	NGNE Neurogene Inc.	Sale(S)	600	$36.02	$21,613	Direct
Jul 2, 2026	NGNE Neurogene Inc.	Sale(S)	1,530	$35.23	$53,897	Direct
Jul 2, 2026	NGNE Neurogene Inc.	Sale(S)	2,531	$34.58	$87,519	Direct
Jul 1, 2026	NGNE Neurogene Inc.	Sale(S)	739	$34.06	$25,170	Direct
May 6, 2026	NGNE Neurogene Inc.	Sale(S)	4,800	$30.07	$144,351	Direct
May 6, 2026	NGNE Neurogene Inc.	Sale(S)	4,800	$32.44	$155,692	Direct
Mar 26, 2026	NGNE Neurogene Inc.	Sale(S)	2,558	$21.62	$55,316	Direct
Mar 13, 2026	NGNE Neurogene Inc.	Sale(S)	263	$22.02	$5,791	Direct
Mar 13, 2026	NGNE Neurogene Inc.	Sale(S)	2,387	$20.42	$48,748	Direct
Mar 13, 2026	NGNE Neurogene Inc.	Sale(S)	1,395	$21.25	$29,637	Direct
Feb 27, 2026	NGNE Neurogene Inc.	Sale(S)	4,800	$25.11	$120,526	Direct
Feb 20, 2026	NGNE Neurogene Inc.	Award(A)	22,000	-	$0	Direct
Mar 26, 2025	NGNE Neurogene Inc.	Award(A)	20,300	-	-	Direct
Mar 13, 2025	NGNE Neurogene Inc.	Sale(S)	4,501	$16.94	$76,247	Direct
Nov 22, 2024	NGNE Neurogene Inc.	Purchase(P)	24,000	$20.48	$491,400	Direct

1-16 of 16 transactions

About Cvijic Christine Mikail

Cvijic Christine Mikail (SEC CIK 0001543663) files insider reports with the SEC as President and CFO of Neurogene Inc. (NGNE).

Signal8 holds 10 ownership filings by Cvijic Christine Mikail, all Form 4s, filed between Nov 25, 2024 and Jul 7, 2026. Those filings report 16 transactions, from Nov 22, 2024 to Jul 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cvijic Christine Mikail's filings is in NEW YORK, NY.

Recent filings by Cvijic Christine Mikail

Jul 7, 2026: Open-market sale of NGNE shares (Form 4, code S).
Jul 6, 2026: Open-market sale of NGNE shares (Form 4, code S).
Jul 2, 2026: Open-market sales of NGNE shares (2 lines, Form 4, code S).
Jul 1, 2026: Open-market sale of NGNE shares (Form 4, code S).
May 6, 2026: Open-market sales of NGNE shares (2 lines, Form 4, code S).

Other insiders filing for Neurogene Inc. (NGNE)

McMinn Rachel, Chief Executive Officer
Woods Keith, Director
Shafer Christina, Chief Commercial Officer
Jordan Julie, Chief Medical Officer
Cobb Stuart, Chief Scientific Officer
PALEKAR ROHAN, Director

How to read Form 4 transaction codes